Abstract:e13508 Background: Murine double minute-2 (MDM2) has increasing clinic relevance as preclinical and early clinical evidences have showed that the MDM2 inhibitors are promising alternative treatments for patients with MDM2-amplified (-amp) and TP53-wild-type (-WT) tumors by preventing TP53 protein degradation. However, exploration into genomic landscape of MDM2/TP53 across various solid tumors in Chinese patients is still limited. Methods: Formalin-fixed, paraffin-embedded (FFPE) tumor samples were collected from 10010 Chinese patients with solid tumors and subjected to a clinical-grade next-generation sequencing (NGS)-based 450 gene panel testing carried out by a College of American Pathologists (CAP) accredited and Clinical Laboratory Improvement Amendments (CLIA) certified laboratory. Genomic alterations (GAs) including single base substitutions, short and long insertion/deletions (Indels), copy number variations, gene fusions, and rearrangements were analyzed. Tumor mutational burden (TMB) was measured by a NGS algorithm. Results: Amplification of MDM2 occurred in 3.3% of Chinese patients. MDM2-amp was detected most frequently in soft tissue sarcoma (STS, 11.4 %), melanoma (10.3 %) and osteosarcoma (6.3 %). Notably, MDM2-amp was revealed to be mutually exclusive with TP53-mut in most tumor types other than esophageal carcinoma (93.9 %), head and neck carcinoma (68.4%) and ovarian carcinoma (50 %). Tumors with highest frequencies of MDM2-amp/ TP53-WT were melanoma (100%), osteosarcoma (100%) and urothelial carcinoma (100 %). The most common co-altered genes accompanied with MDM2-amp were FRS2 (84%), CDK4 (38%), EGFR (26%), TP53 (17%) and GLI1 (14%). 82.8% patients who had one or more co-alterations potentially targetable with either FDA-approved or investigational agent. Moreover, TMB of MDM2-amp tumors were significantly lower than that of MDM2-WT and MDM2-mutation (-mut) tumors (median TMB: 3.1 vs. 4.6 vs. 10.8, p < 0.001 respectively). Conclusions: MDM2 amplification was found in 3.3% of 10010 Chinese cancer patients, 83.4% of whom harbored wild-type TP53 that were potentially responsive to MDM2 inhibitors. In addition, 82.8% of the patients with MDM2-amp harbored genomic co-alterations and were potentially therapy targetable. This study provided insights into identifying patients who might potentially benefit from anti-MDM2 therapies.

MDM2 Promoter SNP309 is Associated with an Increased Susceptibility to Chronic Lymphocytic Leukemia and Correlates with MDM2 Mrna Expression in Chinese Patients with CLL

MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B cell lymphoma patients treated with rituximab CHOP immunochemotherapy: a report …

Risk of MDM2 SNP309 Alone or in Combination with the P53 Codon 72 Polymorphism in Acute Myeloid Leukemia.

MDM2 SNP309 Contributes to Non‐small Cell Lung Cancer Survival in Chinese

Significance of MDM2-309 Polymorphisms and Induced Corresponding Plasma MDM2 Levels in Susceptibility to Laryngeal Squamous Cell Carcinoma.

Mdm2 Gene Promoter Polymorphism and Risk of Cervical Cancer in Chinese Population

Polymorphisms and Haplotypes in Multidrug Resistance 1 Gene Are Not Associated with Chronic Lymphocytic Leukemia Susceptibility and Prognostic Parameters of Chronic Lymphocytic Leukemia in Chinese Population

MDM2 SNP309 polymorphism is associated with colorectal cancer risk

Mdm2 Promoter Snp309 Is Associated With Risk Of Occurrence And Advanced Lymph Node Metastasis Of Nasopharyngeal Carcinoma In Chinese Population

The Relationship Between MDM2 T309G Polymorphism and Leukemia in the Chinese Population: Evidence from a Meta-Analysis.

[Genetic Polymorphism in MDM2 is Associated with Susceptibility to Colorectal Cancer in a Chinese Population].

Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population.

Comprehensive Profiling of MDM2/TP53 Genomic Aberration in Chinese Patients with Diverse Malignancies.

Polymorphisms of P53 and MDM2 Genes Are Associated with Severe Toxicities in Patients with Non-Small Cell Lung Cancer.

Correlation between MDM2 Gene SNP309 Polymorphisms and Cervical Cancer

S-Mdm4 Mrna Overexpression Indicates A Poor Prognosis And Marks A Potential Therapeutic Target In Chronic Lymphocytic Leukemia

Association of MDM2 Promoter T309G Polymorphism with Oral Cancer Risk: A Meta-Analysis of 3,536 Subjects

A Novel Functional Polymorphism C1797g In The Mdm2 Promoter Is Associated With Risk Of Bladder Cancer In A Chinese Population

A functional polymorphism T309G in MDM2 gene promoter, intensified by Helicobacter pylori lipopolysaccharide, is associated with both an increased susceptibility and poor prognosis of gastric carcinoma in Chinese patients

Genetic Variants in the MDM2 Promoter and Lung Cancer Risk in a Chinese Population.

Two Single-Nucleotide Polymorphisms With Linkage Disequilibrium In The Human Programmed Cell Death 5 Gene 5 ' Regulatory Region Affect Promoter Activity And The Susceptibility Of Chronic Myelogenous Leukemia In Chinese Population